Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A proof-of-concept study on the genomic evolution of Sars-Cov-2 in molnupiravir-treated, paxlovid-treated and drug-naïve patients

15 Dec 2022

Abstract excerpt

Abstract Little is known about SARS-CoV-2 evolution under Molnupiravir and Paxlovid, the only antivirals approved for COVID-19 treatment. By investigating SARS-CoV-2 variability in 8 Molnupiravir-treated, 7 Paxlovid-treated and 5 drug-naïve individuals at 4 time-points (Days 0-2-5-7), a higher genetic distance is found under Molnupiravir pressure compared to Paxlovid and no-drug pressure...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to COVID-19 Clinical Research Studies
Share to SARS-CoV-2 and COVID-19 Research
Share to Viral Infections and Outbreaks Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36522489
DOI: 10.1038/s42003-022-04322-8

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A proof-of-concept study on the genomic evolution of Sars-Cov-2 in molnupiravir-treated, paxlovid-treated and drug-naïve patientsPMID 36522489Read ↗

Genomic Evolution of Sars-Cov-2 in Molnupiravir-Treated Patients Compared to Paxlovid-Treated and Drug-Naïve Patients: A Proof-of-Concept StudySemantic proximity Read ↗

Genetic surveillance of SARS-CoV-2 M <sup>pro</sup> reveals high sequence and structural conservation prior to the introduction of protease inhibitor PaxlovidSemantic proximity Read ↗

A molnupiravir-associated mutational signature in global SARS-CoV-2 genomesSemantic proximity Read ↗

A molnupiravir-associated mutational signature in global SARS-CoV-2 genomes.Semantic proximity Read ↗

Genetic Surveillance of SARS-CoV-2 M pro Reveals High Sequence and Structural Conservation Prior to the Introduction of Protease Inhibitor PaxlovidSemantic proximity Read ↗

Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitorsSemantic proximity Read ↗

The Mutation Profile of SARS-CoV-2 Is Primarily Shaped by the Host Antiviral Defense.Semantic proximity Read ↗

Monitoring for SARS-CoV-2 drug resistance mutations in broad viral populationsSemantic proximity Read ↗

Effect of molnupiravir on SARS-CoV-2 evolution in immunocompromised patients: a retrospective observational study.Semantic proximity Read ↗

Molnupiravir increases SARS-CoV-2 genome diversity and complexity: A case-control cohort study.Semantic proximity Read ↗

Evolution of SARS-CoV-2 Viral Mutations in Individuals with Prolonged Infections.Semantic proximity Read ↗

RdRp mutations are associated with SARS-CoV-2 genome evolutionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.